José L. Jiménez: Curriculum Vitae

Contact Information

Novartis Pharma A.G.
Fabrikstrasse 2, 4056 Basel, Switzerland

orcid.org/0000-0002-8809-2717
: jose_luis.jimenez@novartis.com
web: jjimenezm1989.github.io

Research Interests

Bayesian methods, Clinical trials, Survival analysis.

Education

Politecnico di Torino & **Università degli Studi di Torino**, Italy
Ph.D. in Pure and Applied Mathematics (Statistics) **2015 - 2018**

- Ph.D. Thesis Topic: *Innovative adaptive designs in oncology clinical trials with drug combinations*
- Supervisor: Mauro Gasparini. Co-advisor: Mourad Tighiouart [Cedars-Sinai Medical Center, USA]

Universidad Autónoma de Madrid, Spain
M.Sc. in Computer Science and Statistics **2013 - 2015**

Universidad Complutense de Madrid, Spain
B.Sc. in Statistics **2009 - 2013**

Current Position

Statistician **10/2018 - Present**
Novartis, Basel, Switzerland

Past Positions

Marie Curie Early Stage Researcher (Assegnista di Ricerca [SECS-S/01]) **10/2015 - 09/2018**
Politecnico di Torino, Department of Mathematical Sciences, Turin, Italy

Statistician **04/2013 - 03/2015**
PharmaMar, Madrid, Spain

Statistician **01/2012 - 03/2013**
GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain

Research Visits

Cedars-Sinai Medical Center, Los Angeles, USA **10/2017 - 12/2017**
Biostatistics and Bioinformatics Research Center. Supervisor: Mourad Tighiouart.

Novartis Pharma AG, Basel, Switzerland **04/2017 - 06/2017**
Statistical Methodology Group. Supervisor: Byron Jones.

Cedars-Sinai Medical Center, Los Angeles, USA **04/2016 - 06/2016**
Biostatistics and Bioinformatics Research Center. Supervisor: Mourad Tighiouart.

Awards

Marie Skłodowska-Curie Doctoral Fellowship. European Commission. **2015 - 2018**
Travel award. XVth Spanish Biometric Conference and Vth Ibero-American Biometric Meeting **2015**

Publications

Summary of Scientific Achievements (Google Scholar):
Publications: 9 — Total citations: 47 — h-index: 4 — i-index: 2

Published Articles [peer-reviewed]

1. **Jiménez, J. L.** and Tighiouart, M. (2022+). Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*. [Accepted for publication] [issn: 1467-9876]

2. Magirr, D. and **Jiménez, J. L.** (2022) Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance. *Clinical Trials*, 19(2), 201-210. [issn: 1740-7753]

3. **Jiménez, J. L.** (2022). Quantifying treatment differences in confirmatory trials under non-proportional hazards. *Journal of Applied Statistics*, 49(2), 466-484. [issn: 1360-0532]

4. **Jiménez, J. L.**, Niewczas, J., Bore, A. and Burman, C.F. (2021). A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching. *Plos one*, 16(11), e0259178. [issn: 1932-6203]

5. **Jiménez, J. L.**, Stalbovskaya, V. and Jones, B. (2020). Response to comments on "Properties of the weighted log-rank test in the design of confirmatory studies with delayed effect" by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18: 287 – 303, doi: 10.1002/pst.1923. *Pharmaceutical statistics*, 19(5), 736–740. [issn: 1539-1612]

6. **Jiménez, J. L.**, Kim, S. and Tighiouart, M. (2020). A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations. *Biometrical Journal*, 62(5), 1300-1314. [issn: 1521-4036]

7. **Jiménez, J. L.**, Stalbovskaya, V. and Jones, B. (2019). Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects. *Pharmaceutical statistics*, 18(3), 287-303. [issn: 1539-1612]

8. **Jiménez, J. L.**, Tighiouart, M. and Gasparini, M. (2019). Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents. *Biometrical Journal*, 61(2), 319-332. [issn: 1521-4036]

Book Chapters [peer-reviewed]

9. **Jiménez, J. L.**, Diniz, M.A., Rogatko, A., and Tighiouart, M. (2021). Designs of Early Phase Cancer Trials with Drug Combinations. In *Modern Statistical Methods for Health Research* (pp. 131-160). Springer, Cham. [issn: 2524-7743]

Manuscripts Under Review

- Magirr, D. and **Jiménez, J. L.** Stratified modestly-weighted log-rank tests in settings with an anticipated delayed separation of survival curves. *arXiv:2201.10445* [Submitted]
- Tighiouart, M., **Jiménez, J. L.**, Diniz, M.A. and Rogatko, A. Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value? *arXiv:2208.05726* [Submitted]
- **Jiménez, J. L.** and Zheng, H. A Bayesian adaptive design for dual-agent phase I-II cancer clinical trials combining efficacy data across stages. *arXiv:2106.08277* [Submitted]
- **Jiménez, J. L.** and Tighiouart, M. A flexible Bayesian phase I-II design for the combination of targeted therapies. [Submitted]

Presentations

Invited Presentations

[**2022**] 7th Early Phase Adaptive Trials Workshop. Cambridge, UK.
[**2022**] COMPSTAT 2022. International Conference on Computational Statistics. Bologna, Italy.
[**2021**] PSI [Statisticians in the Pharmaceutical Industry] One-Day Meeting: Non-proportional hazards and applications in immuno-oncology. Online.
[**2019**] ISBS 2019. International Symposium in Biopharmaceutical Statistics. Kyoto, Japan.
[**2019**] Symposium on Innovative Statistical Methods in Oncology [Organized by Servier]. Paris, France.

Contributed Oral and Poster Presentations

[**2021**] ISBA [International Society of Bayesian Analysis] World Meeting. Online. [**2018**] EFSPI Workshop. Basel, Switzerland. [**2018**] IBC [International Biometric Conference]. Barcelona, Spain. [**2018**] BAYES Workshop. Cambridge, UK. [**2017**] ISCB Conference. Vigo, Spain. [**2017**] PSI [Statisticians in the Pharmaceutical Industry] Annual Conference. London, UK. [**2015**] SBC [Spanish Biometric Conference]. Bilbao, Spain.

Funding and Grants

Improving Design, Evaluation and Analysis of early drug development Studies (IDEAS). Horizon 2020 Research and Innovation - Marie Sklodowska-Curie Programme (633567). Role: Member. PI: Thomas Jaki.

Design of cancer phase I/II clinical trials using drug combinations of cytotoxic and biologic agents. National Cancer Institute (R01CA188480). Role: Member. PI: Mourad Tighiouart.

Service to Profession

Journal Referee

Biometrical Journal; Pharmaceutical Statistics; Statistical Methods in Medical Research.

Organization of Scientific Events

Local committee of IBC 2018 Conference. Barcelona, Spain. **2018**
Scientific and **Local** committee of the 5th Early Phase Adaptive Trials Workshop. Turin, Italy. **2016**

Membership to Scientific Societies

International Society for Clinical Biostatistics [**ISCB**], International Biometric Society: Region Austria and Switzerland [**ROeS**], International Society for Bayesian Analysis [**ISBA**].

Skills

Languages: English (*fluent*), German (*intermediate*), Italian (*fluent*), Spanish (*native*)
Software: `R` (*advanced*), `JAGS` (*advanced*), LaTeX(*advanced*)

References

References available upon request